TWI709374B - 包含降低血糖之乳酸菌菌株之食品組合物以及醫藥組合物之用途 - Google Patents
包含降低血糖之乳酸菌菌株之食品組合物以及醫藥組合物之用途 Download PDFInfo
- Publication number
- TWI709374B TWI709374B TW108120798A TW108120798A TWI709374B TW I709374 B TWI709374 B TW I709374B TW 108120798 A TW108120798 A TW 108120798A TW 108120798 A TW108120798 A TW 108120798A TW I709374 B TWI709374 B TW I709374B
- Authority
- TW
- Taiwan
- Prior art keywords
- strain
- lactic acid
- acid bacteria
- lactobacillus
- blood sugar
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 154
- 239000004310 lactic acid Substances 0.000 title claims abstract description 77
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 77
- 241000894006 Bacteria Species 0.000 title claims abstract description 75
- 239000008280 blood Substances 0.000 title claims abstract description 48
- 210000004369 blood Anatomy 0.000 title claims abstract description 48
- 235000013305 food Nutrition 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract description 22
- 239000008103 glucose Substances 0.000 title abstract description 22
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 26
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 26
- 241001468157 Lactobacillus johnsonii Species 0.000 claims abstract description 26
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 26
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 24
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 24
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 23
- 235000000346 sugar Nutrition 0.000 claims description 44
- 230000000694 effects Effects 0.000 claims description 20
- 238000011161 development Methods 0.000 claims description 13
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000006186 oral dosage form Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000013618 yogurt Nutrition 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 235000016213 coffee Nutrition 0.000 claims description 2
- 235000013353 coffee beverage Nutrition 0.000 claims description 2
- 235000015140 cultured milk Nutrition 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 23
- 108091006277 SLC5A1 Proteins 0.000 description 18
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 18
- 102000058080 Glucose Transporter Type 5 Human genes 0.000 description 16
- 108091006301 SLC2A5 Proteins 0.000 description 16
- 238000001962 electrophoresis Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 201000010897 colon adenocarcinoma Diseases 0.000 description 9
- 208000029742 colonic neoplasm Diseases 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 229930091371 Fructose Natural products 0.000 description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
- 239000005715 Fructose Substances 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 5
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- RLNYDAFUTZRAIW-UHFFFAOYSA-N 2-ncdc Chemical compound [O-][N+](=O)C1=CC(C(=O)O)=CC=C1OC(=O)N(C=1C=CC=CC=1)C1=CC=CC=C1 RLNYDAFUTZRAIW-UHFFFAOYSA-N 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 3
- 108091052347 Glucose transporter family Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YKXCWZVUWWQSAV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YKXCWZVUWWQSAV-BTVCFUMJSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 235000019543 dairy drink Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 229940074439 potassium sodium tartrate Drugs 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229940062328 actos Drugs 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940000806 amaryl Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940062310 avandia Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical group O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 108700004813 glycosylated insulin Proteins 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940090473 januvia Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- QFYXSLAAXZTRLG-UHFFFAOYSA-N pyrrolidine-2,3-dione Chemical class O=C1CCNC1=O QFYXSLAAXZTRLG-UHFFFAOYSA-N 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229940110862 starlix Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1232—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt in powdered, granulated or dried solid form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/02—Making cheese curd
- A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
- A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/061—Addition of, or treatment with, microorganisms
- A23C19/062—Addition of, or treatment with, microorganisms using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/151—Johnsonii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/181—Salivarius
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
Abstract
一種用於調節血糖之乳酸菌菌株之食品組合物以及醫藥組合物,包含經分離的乳酸菌菌株,其選自寄存編號為BCRC 910404的羅伊氏乳酸桿菌(Lactobacillus reuteri)GL-104菌株、寄存編號為BCRC 910437的唾液乳酸桿菌(Lactobacillus salivarius)AP-32菌株、寄存編號為BCRC 910813的嗜酸乳酸桿菌(Lactobacillus acidophilus)TYCA06菌株、以及寄存編號為BCRC 910438的約氏乳酸桿菌(Lactobacillus johnsonii)MH-68菌株的至少其中之一或組合。
Description
本發明是有關一種食品組合物及醫藥組合物,特別是一種包含降低血糖之乳酸菌菌株之食品組合物以及醫藥組合物。
近年來,由於飲食和生活方式的變化,代謝症候群已成為越來越普遍的疾病,其中,高血糖可能導致糖尿病。糖尿病是一種長期代謝紊亂所造成的疾病,且可能與一些併發症有關,包括心血管疾病、中風、失明、腎衰竭或阿茲海默症,因此,高血糖症之預防與治療值得關注。
傳統用於治療高血糖症狀是使用口服降血糖藥,口服降血糖藥可分為六種,包含:1)磺醯尿素類,例如:Amaryl(瑪爾胰),Glibenclamide(血糖平),Minidiab(滅糖尿),Diamicron(岱蜜克龍)。2)雙胍類,例如:Glucophage(庫魯化錠)。3)唑烷二酮類,例如:Actos(愛妥糖錠),Avandia(梵蒂雅錠)。4)美格替耐類,例如Novonorm(諾和隆錠),Starlix(使糖立釋膜衣錠)。5)α型雙糖分解酶抑制劑,例如Glucobay(醣祿錠)。6)雙胜肽蛋白水解酶抑制劑,例如Januvia(佳糖維)。
然而,口服降血糖藥都具有低血糖或腸胃障礙等副作用。此外,隨著服藥時間增加,最終藥物也會失去效果,迫使病人開始注射胰島素。每日必須測量血糖及注射胰島素對於病患的生活品質具有很大的影響。因此,發展一種方便、安全、低副作用且可長期控制血糖之醫療輔助營養補充品有其迫切性。
目前僅有少數菌株經實驗過程發現具備有調節血糖之活性效果的乳酸菌菌株被確認。而乳酸菌對身體健康的功能在於菌株(strain)的特異性而非菌種(species)(Guidelines for the evaluation of probiotics in food;Report of joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food;London Ontario,Canada April 30 and May 1,2002:1-7)。舉例而言,2017年Singh等人所發表的文獻(Beneficial Microbes,2017;8(2):243-255)中,作者以鼠李糖乳酸桿菌(Lactobacillus rhamnosus)餵食第二型糖尿病老鼠,測試該乳酸菌是否能改善糖尿病的症狀。餵食NCDC 17菌株及GG菌株6週後,進行口服葡萄糖耐受性試驗(Oral Glucose Tolerance Test,OGTT)。結果顯示NCDC 17菌株的降血糖能力明顯優於GG菌株,且兩株菌株在控制空腹血糖的能力也具有明顯差異。此外,只有NCDC 17菌株具有控制血中胰島素、醣化血色素、三酸甘油脂、及膽固醇的效果,而GG菌株則無此效果,顯示雖然是同一種乳酸桿菌,但是對改善糖尿病症狀的效益是有菌株特異性的。
綜上所述,開發具有調節血糖功效的功能性益生菌是目前需努力的目標。
本發明提供一種包含乳酸菌菌株的食品組合物及醫藥組合物,其可降低血糖,進而用於預防及/或治療糖尿病。
本發明一實施例之乳酸菌菌株在製備降低血糖之食品組合物之用途,其中食品組合物包含具有降低血糖之活性效果之乳酸菌菌株,該乳酸菌菌株選自以下至少其中之一經分離的乳酸菌菌株:羅伊氏乳酸桿菌(Lactobacillus reuteri)GL-104菌株,寄存編號為BCRC 910404;唾液乳酸桿菌(Lactobacillus salivarius)AP-32菌株,寄存編號為BCRC 910437;嗜酸乳酸桿菌(Lactobacillus acidophilus)TYCA06菌株,寄存編號為BCRC 910813;以及約氏乳酸桿菌(Lactobacillus johnsonii)MH-68菌株,寄存編號為BCRC 910438,上述菌株均寄存於財團法人食品工業發展研究所,以及生理上可接受的賦形劑或稀釋劑。。
本發明另一實施例之乳酸菌菌株在製備降低血糖之醫藥組合物之用途,其中醫藥組合物包含具有降低血糖之活性效果之乳酸菌菌株,該乳酸菌菌株選自以下至少其中之一經分離的乳酸菌菌株:羅伊氏乳酸桿菌(Lactobacillus reuteri)GL-104菌株,寄存編號為BCRC 910404;唾液乳酸桿菌(Lactobacillus salivarius)AP-32菌株,寄存編號為BCRC 910437;嗜酸乳酸桿菌(Lactobacillus acidophilus)TYCA06菌株,寄存編號為BCRC 910813;以及約氏乳酸桿菌(Lactobacillus johnsonii)MH-68菌株,寄存編號為BCRC 910438,上述菌株均寄存於財團法人食品工業發展研究所,以及醫藥上可接受的賦形劑或稀釋劑。
以下藉由具體實施例配合所附的圖式詳加說明,當更容易瞭解本發明之目的、技術內容、特點及其所達成之功效。
圖1為一柱狀圖,顯示多種乳酸菌菌株之單一單醣的代謝能力。
圖2為一柱狀圖,顯示多種乳酸菌菌株之混和單醣的代謝能力。
圖3為一電泳圖,顯示人類結腸腺癌細胞以及乳酸菌菌株在單一單醣環境下共同培養之SGLT1及GLUT5的基因表現。
圖4為一柱狀圖,顯示量化圖3之電泳圖中GLUT5的基因表現。
圖5為一柱狀圖,顯示量化圖3之電泳圖中SGLT1的基因表現。
圖6為一電泳圖,顯示人類結腸腺癌細胞以及乳酸菌菌株在混和單醣環境下共同培養之SGLT1及GLUT5的基因表現。
圖7為一柱狀圖,顯示量化圖6之電泳圖中GLUT5的基因表現。
圖8為一柱狀圖,顯示量化圖6之電泳圖中SGLT1的基因表現。
以下將詳述本發明之各實施例,並配合圖式作為例示。除了這些詳細說明之外,本發明亦可廣泛地施行於其它的實施例中,任何所述實施例的輕易替代、修改、等效變化都包含在本發明之範圍內,並以申請專利範圍為準。在說明書的描述中,為了使讀者對本發明有較完整的瞭解,提供了許多特定細節;然而,本發明可能在省略部分或全部特定細節的前提下,仍可實施。此外,眾所周知的步驟或元件並未描述於細節中,以避免對本發明形成不必要之限制。圖式中相同或類似之元件將以相同或類似符號來表示。特別注意的是,圖式僅為示意之用,並非代表元件實際之尺寸或數量,有些細節可能未完全繪出,以求圖式之簡潔。
本發明所述之乳酸菌菌株之冷凍乾燥培養物已於寄存於財團法人食品工業發展研究所(地址為台灣新竹市食品路331號)。寄存的詳細資料如以下表1所示。
如表1所列已寄存的四株乳酸菌中,寄存編號為BCRC 910404的羅伊氏乳酸桿菌(Lactobacillus reuteri)GL-104菌株、寄存編號為BCRC 910437的唾液乳酸桿菌(Lactobacillus salivarius)AP-32菌株、寄存編號為BCRC 910813的嗜酸乳酸桿菌(Lactobacillus acidophilus)TYCA06菌株、以及寄存編號為BCRC 910438的約氏乳酸桿菌(Lactobacillus johnsonii)MH-68菌株具有調節血糖的生理活性。需說明的是,本發明所屬技術領域的技術人員可以理解本發明所述之調節血糖大多為降低血糖,期能達到預防及/或治療糖尿病的功效。因此,本發明所述之生理活性不限於調節血糖、控制血糖或降低血糖等字面所述代表的意義。
本發明之一實施例之包含降低血糖之乳酸菌菌株的食品組合物,其包含經分離的乳酸菌菌株以及生理上可接受的賦形劑或稀釋劑。經分離的乳酸菌菌選自以下至少其中之一之乳酸桿菌菌株:羅伊氏乳酸桿菌(Lactobacillus reuteri)GL-104菌株,寄存編號為BCRC 910404、唾液乳酸桿菌(Lactobacillus salivarius)AP-32菌株,寄存編號為BCRC 910437、嗜酸乳酸桿菌(Lactobacillus acidophilus)TYCA06菌株,寄存編號為BCRC 910813、以及約氏乳酸桿菌(Lactobacillus johnsonii)MH-68菌株,寄存編號為BCRC 910438。上述乳酸菌菌株可為具有活性或去活性的菌株,且均已寄存於財團法人食品工業發展研究所。
於食品組合物之實施例中,生理上可接受之賦形劑或稀釋劑可為一食品,舉例而言,食品可包含但不限於乳製飲品、茶、咖啡或以上之組合,其
中乳製飲品可包含醱酵乳、優格、乳酪或乳製飲品乳粉。此外,本發明之食品組合物中的乳酸菌菌株的數量可為106CFU以上,較佳地,乳酸菌菌株之數量可為1010CFU以上。
本發明之一實施例之包含降低血糖之乳酸菌菌株的醫藥組合物,其包含經分離的乳酸菌菌株以及醫藥上可接受的賦形劑或稀釋劑。經分離的乳酸菌菌選自以下至少其中之一之經分離的乳酸桿菌菌株:羅伊氏乳酸桿菌(Lactobacillus reuteri)GL-104菌株,寄存編號為BCRC 910404、唾液乳酸桿菌(Lactobacillus salivarius)AP-32菌株,寄存編號為BCRC 910437、嗜酸乳酸桿菌(Lactobacillus acidophilus)TYCA06菌株,寄存編號為BCRC 910813、以及約氏乳酸桿菌(Lactobacillus johnsonii)MH-68菌株,寄存編號為BCRC 910438。上述乳酸菌菌株可為具有活性或去活性的菌株,且均已寄存於財團法人食品工業發展研究所。
於一實施例中,醫藥組合物可包含口服劑型。舉例而言,口服劑型可為錠劑、膠囊、溶液劑及粉劑等。此外,本發明之醫藥組合物中的乳酸菌菌株的數量可為106CFU以上,較佳地,乳酸菌菌株之數量可為1010CFU以上。
需說明的是,由本發明之下述試驗結果可知,並非每一株測試的乳酸菌菌株皆具有相同的代謝醣類的能力。初步篩選出的菌株在進行與腸道細胞共培養的試驗中,對於腸道細胞內與糖類吸收以進入血液循環相關之基因表現的影響有很大程度的差異存在。需提醒的是,本發明所請求保護之乳酸菌菌株僅包含寄存於財團法人食品工業發展研究所之羅伊氏乳酸桿菌(Lactobacillus reuteri)GL-104菌株,寄存編號BCRC 910404、唾液乳酸桿菌(Lactobacillus salivarius)AP-32菌株,寄存編號BCRC 910437、嗜酸乳酸桿菌(Lactobacillus acidophilus)TYCA06菌株,寄存編號BCRC 910813、及約氏乳酸桿菌
(Lactobacillus johnsonii)MH-68菌株,寄存編號BCRC 910438,並非廣泛地包含上述相同菌種的所有菌株或本發明測試過的菌株。
在本實施例中,使用的乳酸菌包含唾液乳酸桿菌(Lactobacillus salivarius)AP-32菌株、gL-28菌株及gL-65菌株、約氏乳酸桿菌(Lactobacillus johnsonii)MH-68菌株及gL-84菌株、羅伊氏乳酸桿菌(Lactobacillus reuteri)GL-104菌株、gL-21菌株及gL-22菌株、嗜酸乳酸桿菌(Lactobacillus acidophilus)TYCA06菌株、TYCA01菌株及gL-97菌株、副乾酪乳酸桿菌(Lactobacillus paracasei)GL-106菌株及GL-156菌株、鼠李糖乳酸桿菌(Lactobacillus rhamnosus)CT-53菌株、GL-165菌株、F-1菌株及bv-77菌株、植物乳酸桿菌(Lactobacillus plantarum)LPL28菌株及gL-305菌株、乾酪乳酸桿菌(Lactobacillus casei)CS-773
菌株及gL-10菌株、瑞士乳酸桿菌(Lactobacillus helveticus)RE-78菌株及gL-72菌株、屎腸球菌(Enterococcus faecium)YM-66菌株及YM-73菌株、動物雙歧桿菌乳雙歧亞種(Bifidobacterium animalis subsp.lactis)BB-115菌株及CP-9菌株、長雙歧桿菌(Bifidobacterium longum)BLI-02菌株、兩歧雙歧桿菌(Bifidobacterium bifidum)Bd-2379菌株、BUO87菌株及Bf-688菌株以及短雙歧桿菌(Bifidobacterium breve)Bv-889菌株。上述菌株是以50%甘油保存於-80℃。使用前,以含有0.05%半胱胺酸之MRS broth(DIFCO),37℃下活化(24小時)二次後使用。
將上述菌株各接種1×108CFU於培養液中,雙歧桿菌的培養液另添加0.05%半胱胺酸,其中培養液為MRS培養液(含葡萄糖60mg/ml)。接著,在37℃培養箱培養20小時後收集上清液,以DNS試劑(27.4mM 3,5-Dinitrosalicylic acid,524mM Sodium hydroxide及879mM Potassium sodium tartrate)分析還原糖濃度,進而推算各菌株的單醣利用率(%)。單醣利用率是使用以下公式計算得知:
請參照圖1,結果顯示羅伊氏乳酸桿菌、唾液乳酸桿菌、約氏乳酸桿菌、和嗜酸乳酸桿菌相較於其他乳酸菌及雙岐桿菌具有較佳的代謝單醣的能力,其中符號*表示p值<0.05,亦即比對的兩方具有顯著差異;符號**表示p值<0.01,亦即比對的兩方具有非常顯著的差異。在這幾種乳酸桿菌中代謝單醣能力最好的菌株為本發明之羅伊氏乳酸桿菌GL-104菌株、唾液乳酸桿菌AP-32菌株、約氏乳酸桿菌MH-68菌株和嗜酸乳酸桿菌TYCA06菌株。值得一提的是,即使是相同菌種,不同的菌株對於血糖調節的能力仍有所差異。舉例而言,在羅伊氏乳酸桿菌的三株菌株中,GL-104菌株相較於gL-21菌株及gL-22菌株有明顯較佳的單醣代謝能力,顯見乳酸菌對於調節血糖的能力在於菌株(strain)的特異性而非菌種(species)。
在本實施例中,將上述菌株各接種1×108CFU於培養液中,其中培養液為MFG培養液(含葡萄糖20mg/ml、果糖20mg/ml、和半乳糖20mg/ml)。接著,在37℃培養箱培養20小時後收集上清液,以DNS試劑(27.4mM的3,5-Dinitrosalicylic acid,524mM Sodium hydroxide及879mM Potassium sodium tartrate)分析還原糖濃度,進而推算各菌株的混和單醣利用率(%)。。
請參照圖2,結果顯示羅伊氏乳酸桿菌、唾液乳酸桿菌、約氏乳酸桿菌、和嗜酸乳酸桿菌相較於其他乳酸菌及雙岐桿菌在混和單醣環境下具有較佳的代謝混和單醣的能力,其中符號*表示p值<0.05,亦即比對的兩方具有顯著差異;符號**表示p值<0.01,亦即比對的兩方具有非常顯著的差異。圖2所示之結果,又以本發明之羅伊氏乳酸桿菌GL-104菌株、唾液乳酸桿菌AP-32菌株、約氏乳酸桿菌MH-68菌株及嗜酸乳酸桿菌TYCA06菌株代謝混和單醣的能力最強。
可以理解的是,食物中含有各種不同醣類,經過腸胃道消化之後,除了主要的葡萄糖之外,仍會存在其他單醣類對血糖有所影響。因此,若能對單一單醣(葡萄糖)或混和單醣(葡萄糖、果糖、半乳糖)都具有強代謝能力的菌株對於血糖的調節應會有較佳的效果。
血糖的升高主要是來自腸道內食物中的糖分經過消化後,由腸道黏膜細胞吸收再轉運至血管內,這與小腸黏膜細胞的第一型鈉離子依賴型葡萄糖轉運蛋白(sodium-glucose linked transporter 1,SGLT1)及葡萄糖載體蛋白(Glucose transporter 5,GLUT5)具有相關性。其中,SGLT1與葡萄糖由腸道進入腸道黏膜細胞有關,GLUT5則與果糖由腸道進入腸道黏膜細胞有關。因此,若
SGLT1表現降低,可以減緩葡萄糖的吸收,也就能減緩糖分進入血中,進而減緩血糖升高。
人類結腸腺癌細胞(Caco-2)是一種用於研究腸道養分和藥物吸收運輸狀況的良好體外模型,因此,將乳酸菌菌株與人類結腸腺癌細胞(Caco-2)共同培養,透過分析人類結腸腺癌細胞中SGLT1及GLUT5的基因表現,可以了解乳酸菌菌株對於調節血糖的影響,進而篩選出具有降低血糖功能的乳酸菌菌株。
在本實施例中,將人類結腸腺癌細胞(Caco-2)接種至6孔平板的平板內(每孔4×105cell),培養隔夜。每孔加入8×108CFU乳酸菌菌株再共培養20小時後,收集細胞並用TRIZOL試劑並萃取總RNA。接著,使用反轉錄酶(reverse transcripatase)將RNA反轉錄為cDNA,再使用定量即時聚合酶鏈鎖反應(Quantitative real time polymerase chain reaction,Q-PCR)分析第一型鈉離子依賴型葡萄糖轉運蛋白(sodium-glucose linked transporter 1,SGLT1)及葡萄糖載體蛋白(Glucose transporter 5,GLUT5)的基因表現量。其中,對照組為僅培養人類結腸腺癌細胞,不加入乳酸菌共同培養的組別。
在本實施例中,使用的乳酸菌包含:羅伊氏乳酸桿菌GL-104菌株、唾液乳酸桿菌AP-32菌株、約氏乳酸桿菌MH-68菌株、嗜酸乳酸桿菌TYCA06菌株及鼠李糖乳酸桿菌F-1菌株。另外,本實施例將各組細胞分別培養於hMEM培養液(高葡萄糖培養液,含葡萄糖4.5mg/ml)及hmMEM(高混合單醣培養液,含葡萄糖1.5mg/ml、果糖1.5mg/ml及半乳糖1.5mg/ml)以分析不同的乳酸菌在單一單醣環境下及混和單醣環境下對於調節血糖之SGLT1及GLUT5的基因表現影響,結果如圖3至圖8所示。
圖3為各組細胞在單一單醣環境下的基因表現之電泳圖,其中以甘油醛3-磷酸脫氫酶(Glyceraldehyde 3-phosphate dehydrogenase,GAPDH)的基因表現作為控制組,圖4為量化圖3之電泳圖中GLUT5之基因表現的柱狀圖,圖5為
量化圖3之電泳圖中SGLT1之基因表現的柱狀圖,其中符號***表示p值<0.001,符號**表示p值<0.01,亦即統計學上具有非常顯著的差異。從圖3至圖5的結果可發現,相較於對照組MEM(葡萄糖培養液),本發明之羅伊氏乳酸桿菌GL-104菌株、唾液乳酸桿菌AP-32菌株、約氏乳酸桿菌MH-68菌株、嗜酸乳酸桿菌TYCA06菌株可在單一單醣環境下抑制人類結腸腺癌細胞中SGLT1及GLUT5的基因表現,其中本發明之唾液乳酸桿菌AP-32菌株、羅伊氏乳酸桿菌GL-104菌株、約氏乳酸桿菌MH-68菌株及嗜酸乳酸桿菌TYCA06菌株有極佳的抑制效果。
圖6為各組細胞在混和單醣環境下的基因表現電泳圖,其中以GAPDH的基因表現作為控制組,圖7為量化圖6之電泳圖中GLUT5之基因表現的柱狀圖,圖8為量化圖6之電泳圖中SGLT1之基因表現的柱狀圖,其中符號***表示p值<0.001,符號**表示p值<0.01,亦即統計學上具有非常顯著的差異。從圖6至圖8的結果可發現,相較於控制組MEM(葡萄糖培養液),本發明之羅伊氏乳酸桿菌GL-104菌株、唾液乳酸桿菌AP-32菌株、約氏乳酸桿菌MH-68菌株、嗜酸乳酸桿菌TYCA06菌株可在混和單醣環境下抑制人類結腸腺癌細胞中SGLT1及GLUT5的基因表現,其中本發明之唾液乳酸桿菌AP-32菌株、羅伊氏乳酸桿菌GL-104菌株、約氏乳酸桿菌MH-68菌株及嗜酸乳酸桿菌TYCA06菌株有極佳的抑制效果。
由上述可知,本發明之唾液乳酸桿菌AP-32菌株、羅伊氏乳酸桿菌GL-104菌株、約氏乳酸桿菌MH-68菌株及嗜酸乳酸桿菌TYCA06菌株對於SGLT1及GLUT5的基因表現具有抑制的效果,進而會對葡萄糖及果糖進入腸道黏膜細胞產生影響,也因此達到降低血糖的功效。另需說明的是,相較於鼠李糖乳酸桿菌F-1菌株,本發明之唾液乳酸桿菌AP-32菌株、羅伊氏乳酸桿菌GL-104菌株、約氏乳酸桿菌MH-68菌株及嗜酸乳酸桿菌TYCA06菌株於hMEM培養液(高葡萄糖培養液)及hmMEM培養液(高混合單醣培養液)的環境下,對於SGLT1的基因表現
皆有相對較佳的抑制效果,如圖5以及圖8之結果所示,因此可以減緩葡萄糖的吸收,進而減緩血糖升高。
綜上所述,本發明之乳酸菌菌株具有良好的單醣代謝能力,且可抑制細胞中SGLT1及GLUT5的基因表現而達到降低血糖的功效。相較於傳統的口服降血糖藥物,本發明之包含乳酸菌菌株之食品組合物以及醫藥組合物對人體較無副作用。此外,相較於胰島素注射等侵入性治療方法,本發明之包含乳酸菌菌株之食品組合物以及醫藥組合物可大幅改善病患生活品質,因此可有利於預防或治療糖尿病的應用。
以上所述之實施例僅是為說明本發明之技術思想及特點,其目的在使熟習此項技藝之人士能夠瞭解本發明之內容並據以實施,當不能以之限定本發明之專利範圍,即大凡依本發明所揭示之精神所作之均等變化或修飾,仍應涵蓋在本發明之專利範圍內。
財團法人食品工業發展研究所、2008年10月29日、BCRC 910404
財團法人食品工業發展研究所、2009年7月30日、BCRC 910437
財團法人食品工業發展研究所、2018年1月18日、BCRC 910813
財團法人食品工業發展研究所、2009年7月30日、BCRC 910438
Claims (9)
- 一種乳酸菌菌株在製備降低血糖的食品組合物之用途,其中該食品組合物包含:具有降低血糖之活性效果之乳酸菌菌株,該乳酸菌菌株選自以下至少其中之一經分離的乳酸菌菌株:羅伊氏乳酸桿菌(Lactobacillus reuteri)GL-104菌株,寄存編號為BCRC 910404;唾液乳酸桿菌(Lactobacillus salivarius)AP-32菌株,寄存編號為BCRC 910437;嗜酸乳酸桿菌(Lactobacillus acidophilus)TYCA06菌株,寄存編號為BCRC 910813;以及約氏乳酸桿菌(Lactobacillus johnsonii)MH-68菌株,寄存編號為BCRC 910438,上述菌株均寄存於財團法人食品工業發展研究所;以及生理上可接受的賦形劑或稀釋劑。
- 如請求項1所述之乳酸菌菌株在製備降低血糖的食品組合物之用途,其中該乳酸菌菌株包含羅伊氏乳酸桿菌GL-104菌株以及唾液乳酸桿菌AP-32菌株至少其中之一。
- 如請求項1所述之乳酸菌菌株在製備降低血糖的食品組合物之用途,其中該乳酸菌菌株為具有活性或去活性的菌株。
- 如請求項1所述之乳酸菌菌株在製備降低血糖的食品組合物之用途,其中該賦形劑或稀釋劑為一食品。
- 如請求項4所述之乳酸菌菌株在製備降低血糖的食品組合物之用途,其中該食品包含醱酵乳、優格、乳酪、乳製飲品乳粉、茶、咖啡或以上之組合。
- 一種乳酸菌菌株在製備降低血糖的醫藥組合物之用途,其中該醫藥組合物包含:具有降低血糖之活性效果之乳酸菌菌株,該乳酸菌菌株選自以下至少其中之一經分離的乳酸菌菌株:羅伊氏乳酸桿菌(Lactobacillus reuteri)GL-104菌株,寄存編號為BCRC 910404;唾液乳酸桿菌(Lactobacillus salivarius)AP-32菌株,寄存編號為BCRC 910437;嗜酸乳酸桿菌(Lactobacillus acidophilus)TYCA06菌株,寄存編號為BCRC 910813;以及約氏乳酸桿菌(Lactobacillus johnsonii)MH-68菌株,寄存編號為BCRC 910438,上述菌株均寄存於財團法人食品工業發展研究所;以及醫藥上可接受的賦形劑或稀釋劑。
- 如請求項6所述之乳酸菌菌株在製備降低血糖的醫藥組合物之用途,其中該乳酸菌菌株包含羅伊氏乳酸桿菌GL-104菌株以及唾液乳酸桿菌AP-32菌株至少其中之一。
- 如請求項6所述之乳酸菌菌株在製備降低血糖的醫藥組合物之用途,其中該乳酸菌菌株為具有活性或去活性的菌株。
- 如請求項6所述之乳酸菌菌株在製備降低血糖的醫藥組合物之用途,其中該醫藥組合物為口服劑型。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW108120798A TWI709374B (zh) | 2019-06-14 | 2019-06-14 | 包含降低血糖之乳酸菌菌株之食品組合物以及醫藥組合物之用途 |
CN201910690807.5A CN112075638A (zh) | 2019-06-14 | 2019-07-29 | 包含降低血糖的乳酸菌菌株的食品组合物以及医药组合物 |
US16/599,496 US11612171B2 (en) | 2019-06-14 | 2019-10-11 | Food composition and pharmaceutical composition with strains of lactic acid bacteria and method for modulating blood glucose |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW108120798A TWI709374B (zh) | 2019-06-14 | 2019-06-14 | 包含降低血糖之乳酸菌菌株之食品組合物以及醫藥組合物之用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
TWI709374B true TWI709374B (zh) | 2020-11-11 |
TW202045036A TW202045036A (zh) | 2020-12-16 |
Family
ID=73734290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW108120798A TWI709374B (zh) | 2019-06-14 | 2019-06-14 | 包含降低血糖之乳酸菌菌株之食品組合物以及醫藥組合物之用途 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11612171B2 (zh) |
CN (1) | CN112075638A (zh) |
TW (1) | TWI709374B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109665925A (zh) * | 2019-01-30 | 2019-04-23 | 山东丰悦生物技术有限公司 | 直接吸收的全水溶性生态肥料用新材料蛋白粉生产工艺 |
CN113151056B (zh) * | 2021-03-18 | 2023-01-20 | 仙乐健康科技股份有限公司 | 益生菌组合物、其制备方法和用途 |
TWI777475B (zh) * | 2021-03-30 | 2022-09-11 | 豐華生物科技股份有限公司 | 使用乳酸菌菌株組合來治療第1型糖尿病 |
TWI792249B (zh) * | 2021-03-31 | 2023-02-11 | 豐華生物科技股份有限公司 | 使用乳酸菌菌株的發酵培養物來治療和/或預防幽門螺旋桿菌感染的相關疾病 |
CN115141860A (zh) * | 2021-03-31 | 2022-10-04 | 锦乔生物科技有限公司 | 用于生产γ-胺基丁酸的方法及其所制得的发酵培养物 |
CN113061548A (zh) * | 2021-03-31 | 2021-07-02 | 盐城维康生物科技有限公司 | 一种能增加降血糖效果的嗜酸乳杆菌制剂及其制备方法 |
CN113528383B (zh) * | 2021-07-09 | 2022-03-22 | 浙江大学 | 降血糖乳杆菌zjuids09及其应用 |
TWI820499B (zh) * | 2021-10-26 | 2023-11-01 | 豐華生物科技股份有限公司 | 益生菌液態培養物及其在改善皮膚相關病況上的用途 |
CN115181710B (zh) * | 2022-09-13 | 2022-11-25 | 北京量化健康科技有限公司 | 一株唾液乳杆菌b12wu及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI340021B (en) * | 2010-03-31 | 2011-04-11 | Genmont Biotech Inc | Novel lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof |
TWI639389B (zh) * | 2017-01-24 | 2018-11-01 | 豐華生物科技股份有限公司 | 用於抑制口腔病原菌之乳酸菌菌株之食品、口腔清潔以及醫藥組合物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH107577A (ja) * | 1996-06-17 | 1998-01-13 | Yakult Honsha Co Ltd | 血糖降下剤 |
TWI542353B (zh) * | 2010-04-30 | 2016-07-21 | 豐華生物科技股份有限公司 | 用以抗陰道炎之含乳酸菌食品組合物及醫藥組合物 |
CN102935092B (zh) * | 2010-06-09 | 2014-03-26 | 景岳生物科技股份有限公司 | 新颖乳杆菌及其组合物和在制备改善糖尿病及其并发症药物中的应用 |
CN102309001B (zh) * | 2010-07-01 | 2013-04-03 | 丰华生物科技股份有限公司 | 用于治疗过敏的乳酸菌菌株的食品组合物以及医药组合物 |
CN102835666B (zh) * | 2011-06-20 | 2014-08-13 | 丰华生物科技股份有限公司 | 用于治疗胃溃疡的乳酸菌菌株的食品组合物以及医药组合物 |
CN102835657B (zh) * | 2011-06-20 | 2014-08-20 | 丰华生物科技股份有限公司 | 用以抑制发炎反应及抗阴道炎的含乳酸菌食品组合物及医药组合物 |
GB2524474B (en) * | 2014-03-07 | 2018-01-31 | Genmont Biotech Inc | Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes |
CN106036911A (zh) * | 2016-06-21 | 2016-10-26 | 广州宇晟生物科技有限公司 | 一种调节血糖水平的益生菌膳食组合物及功能食品 |
CN106852939A (zh) * | 2016-11-08 | 2017-06-16 | 江西益盟科技有限公司 | 治疗阴道炎的乳酸菌组合物及其制备方法 |
CN106619742A (zh) * | 2016-11-08 | 2017-05-10 | 江西益盟科技有限公司 | 治疗糖尿病的乳酸菌组合物及其制备方法 |
CN107523526B (zh) * | 2017-10-17 | 2020-05-12 | 无限极(中国)有限公司 | 一种罗伊氏乳杆菌及其用途 |
CN108157973B (zh) * | 2017-12-14 | 2021-04-02 | 上海交通大学医学院附属瑞金医院 | 一种有益糖脂代谢功能的益生菌组合物及其制剂和应用 |
CN109221519A (zh) * | 2018-09-25 | 2019-01-18 | 西安源森生物科技有限公司 | 一种降血糖用低聚糖益生菌固体饮料及其制备方法 |
CN109182207B (zh) * | 2018-10-10 | 2020-10-27 | 北京首佳利华科技有限公司 | 一株具有调节血糖和胆固醇水平等益生功能的嗜酸乳杆菌La-SJLH001及其应用 |
-
2019
- 2019-06-14 TW TW108120798A patent/TWI709374B/zh active
- 2019-07-29 CN CN201910690807.5A patent/CN112075638A/zh active Pending
- 2019-10-11 US US16/599,496 patent/US11612171B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI340021B (en) * | 2010-03-31 | 2011-04-11 | Genmont Biotech Inc | Novel lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof |
TWI639389B (zh) * | 2017-01-24 | 2018-11-01 | 豐華生物科技股份有限公司 | 用於抑制口腔病原菌之乳酸菌菌株之食品、口腔清潔以及醫藥組合物 |
Non-Patent Citations (4)
Also Published As
Publication number | Publication date |
---|---|
CN112075638A (zh) | 2020-12-15 |
US11612171B2 (en) | 2023-03-28 |
US20200390119A1 (en) | 2020-12-17 |
TW202045036A (zh) | 2020-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI709374B (zh) | 包含降低血糖之乳酸菌菌株之食品組合物以及醫藥組合物之用途 | |
CN110604749B (zh) | 动物双歧杆菌a12及其在控制糖尿病或高血脂症特别是体重增加或肥胖中的应用 | |
US8298526B2 (en) | Lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof | |
CN110150669B (zh) | 一种适于糖尿病患者食用的益生菌组合物及其应用 | |
JP5185976B2 (ja) | 糖尿病及びその合併症の改善に使われる組成物、改善方法及び乳酸桿菌分離株 | |
WO2020211831A1 (zh) | 一种具有降血糖功效的益生菌制剂的功能性食品 | |
KR101228035B1 (ko) | 신규한 유산균 및 이를 포함하는 당뇨병 예방 및 치료용 조성물 | |
CN113308421B (zh) | 一种植物乳杆菌bufx及其在代谢综合征中的应用 | |
JP6562934B2 (ja) | 組成物およびスクリーニング方法 | |
EP2392340B1 (en) | Novel lactobacillus strain, composition and use thereof for treating diabetes | |
TW201705969A (zh) | 新穎馬利乳酸桿菌aps1及其用途 | |
CN112274577B (zh) | 包含芭蕉属物种发酵物的组合物的用途及益生质组合物 | |
CN113151070A (zh) | 一株可提高肠道中克里斯藤森菌科相对丰度的发酵乳杆菌 | |
CN115044507B (zh) | 一种治疗和/或预防糖脂代谢异常的微生物组合物及其应用 | |
TWI667344B (zh) | Lactobacillus reuteri strain GMNL-263 and composition thereof capable of improving hypertension | |
CN114426941A (zh) | 副干酪乳杆菌Glu-07及其应用 | |
US20230149482A1 (en) | Composition for improving gut microbiota | |
US20190388484A1 (en) | Lactobacillus reuteri gmnl-263 for improving hypertension and its compositions thereof | |
CN113832085B (zh) | 戊糖乳杆菌bnpv及其应用 | |
US20220105141A1 (en) | Lactobacillus reuteri gmnl-263 for improving hypertension and its compositions thereof | |
CN117070398B (zh) | 一种改善便秘的动物双歧杆菌乳亚种Bi66及其应用、产品和方法 | |
TWI817342B (zh) | 益生質組合物及其用途 | |
US20230144246A1 (en) | Probiotic composition and its method for improving intestinal tract of subject in need thereof | |
TWI835021B (zh) | 益生質組合物及其用途 | |
KR102403578B1 (ko) | 인슐린 저항성 개선제 및 인슐린 저항성 질환 예방용의 건강 보조 식품 |